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Abstract: Ibuprofen (IBU) is a poorly water-soluble non-steroidal anti-inflammatory drug with proven effectiveness for treating inflamma-
tory, musculoskeletal, and rheumatic disorders. Nanocrystals (NCs) have been proposed as drug delivery systems to improve the solubility 
and bioavailability of poorly water-soluble compounds. Ibuprofen NCs (IBU-NCs) have been produced by the melt-emulsification method 
using a combination of Tween®80(1.0%, w/v)/Span®80(0.5%, w/v) as surfactant as these molecules are generally recognized as safe (GRAS) as 
non-toxic, non-irritating and are of low cost. The obtained main particle size (z-Ave) and polydispersity index (PdI) were 159.4 ± 3.265 nm 
and 0.24 ± 0.007, respectively. Lyophilization slightly increased the mean particle size and PdI compared to the non-freeze-dried IBU-NCs. 
The obtained IBU-NCs powders were of white and fine texture. The type and concentration of cryoprotector (trehalose, glucose, sucrose) 
influenced both the size and the in vitro release profile tested in Franz diffusion cells. Due to the smaller z-Ave, NCs:Trehalose (2:1) of 170.6 
± 3.880 nm (0.417 ± 0.050), NCs:Glucose (3:1) of 275.3 ± 8.351 nm (0.144 ± 0.021) and NCs:Sucrose (4:1) of 223.3 ± 10.35 nm (0.402 ± 
0.016) were selected for the in vitro drug release tests. Within the first 6 hours, resuspended lyophilized nanocrystals released between 
50-70% of the drug.
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Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used 
for their analgesic and antipyretic actions (1). Their mechanism of action 
concerns non-selective inhibition of the type 1 cyclooxygenase (COX-
1) and type 2 cyclooxygenase (COX-2), which is listed as its principal 
adverse effects by oral ingestion (2). 
Among NSAIDs, ibuprofen has been recommended to treat 
inflammatory, musculoskeletal and rheumatic disorders (3-5). However, 
the challenge in pharmaceutical development of such drug is due to its 
high plasma protein binding (90-99%), short plasma half-life (2.2 hours) 
with rapid urine removal, reaching the peak plasma concentration in just 
1-2 hours (6). Also, IBF shows lipophilicity, a high partition coefficient 
and low bioavailability through the skin (7).
Many approaches have been exploited to overcome the skin barrier 
for IBF drug delivery. Nanocrystals (NCs) have significant advantages in 
improving the bioavailability of poorly water-soluble drugs, due to their 
high solubilization capacity and the possibility to control the delivery 
rate (5, 8, 9). NCs are homogeneous, optically transparent, of low viscosity, 
thermodynamically stable and can be produced without the need of 
specialized equipment other than to use a few adjuvants (9). 
Nanocrystals have emerged as an interesting drug delivery system for 
clinical usage. It is defined as a nanotechnology-based formulations with 
a particles size below 1000 nanometers and have a stable performance 
by adding an appropriate stabilizer such as polymeric steric stabilizers or 
surfactant in a aqueous medium – nanosuspension (10, 11). 
These stabilizers have an important role in nanosuspension, 
preventing aggregation among nanocrystals due to their high surface 
energy which contributes to aggregation between them. They are largely 
used to overcome the bioavailability and dissolution difficulties of using 
poor water-soluble drugs in traditional pharmaceutical formulations, 
which is one of the chief challenges that scientists face in drugs 
formulations (10, 11). 
The nanoparticle size allows to increase the surface area and, 
consequently, enhance the dissolution velocity according with the 
Noyes-Whitney equation, improving kinetic drug performance. Another 
important characteristic which made nanocrystals a special formulation 
is each nanoparticle contain 100% of the drug inside and a polymeric 
or lipid matrix enclose them, thus, considerable drug concentration 
is transporting to the target cells, enhancing the bioavailability and, 
consequently, achieving an appropriate drug concentration for the 
pharmaceutical effect (9).
The aim of this work has been to develop an ibuprofen nanocrystal 
formulation by melt-emulsification technique, and evaluate the effect 




Ibuprofen has been donated by Medinfar (Amadora, Portugal). 
Polysorbate 80 (Tween®80) was obtained from Uniqema (Everberg, 
Belgium). Trehalose, sucrose, and glucose were purchased from Merck 
S.A. (Lisboa, Portugal). Phosphate buffered saline (pH 7.4), and sorbitan 
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monooleate (Span®80) were purchased from Sigma-Aldrich (Steinheim, Germany). Cellulose membrane with an average pore 
size of 0.22 µm was obtained from Millipore® HA. Ultra-purified water was obtained from the Milli®Q Plus system.
Nanocrystal production by melt emulsification  
The melt-emulsification methodology was used to produce nanocrystals as previously described (3, 4). Ibuprofen 0.25% 
(w/v) was added to the aqueous surfactant solution composed of Tween® 80 (1.0%, w/v) and Span® 80 (0.5%, w/v) heated 
at 80°C. The suspension was homogenized by high shear homogenization in Ultra Turrax® (T25, IKA) for 10 minutes to ob-
tain a coarse emulsion. The obtained emulsion was poured into a high-pressure homogenizer (EmulsiFlex®-C3, Avastin) 
and homogenized at 1000 bar for 20 minutes in the continuous mode under heating at 80°C. Finally, the hot formulation 
was then cooled down using an ice bath for approximately 20 minutes.
Lyophilization 
Nanocrystals were freeze-dried using three different cryoprotectants, trehalose (T), glucose (G) and sucrose (S). Na-
nocrystal dispersions were diluted with aqueous cryoprotectant solutions at 4:1, 3:1 and 2:1 (v/v) prior to freeze-drying, 
and frozen to -80ºC in a freezer immediately before freeze-drying in a Gamma 2-20 freeze dryer (Christ, Osterode a.H., 
Germany) operating at -250/0.025 mBar for a period of 24 h (for the main freezing) and over 6 h drying (12). The lyophilied 
samples were then dispersed in double distilled water and filtered by a 0.22 µm pore membrane and reanalyzed for their 
mean particle size and PI (13).
Particle size analysis
The mean particle size (z-Ave) and polydispersity index (PI) were measured by dynamic light scattering (DLS), in freshly 
prepared nanocrystals, using a particle size analyzer (DelsaNano C Submicron, Beckman Coulter Delsa, Krefeld, Germany). 
The measurements were run in triplicate, recording 10 readings per run (14). 
In vitro release profile
The release profile of ibuprofen from the obtained nanocrystals (before and after freeze-drying) was studied using 
vertical Franz diffusion cells (n = 3 cells/sample). In each cell, a cellulose Millipore HA membrane with an average pore 
size of 0.22 µm was used previously soaked for at least 1 hour with receptor fluid (phosphate-buffered saline (PBS) at pH 
7.4). At pre-determined time intervals, 200 µL of the samples were collected using a syringe, and the same volume was 
replaced with PBS. The samples were analyzed by ultraviolet (UV) assay at 264 nm, in a Synergy™ HT Multi-Mode Microplate 
Reader. PBS at pH 7.4 was used as receptor medium and maintained at 37ºC during the tests (3). 
Results and discussion
Ibuprofen (IBU), a name derived from isobutyl propanoic phenolic acid, is non-steroidal anti-inflammatory drug with 
proven effectiveness for treating pain, fever, and inflammation. IBU is one of the most commonly used non-steroidal an-
ti-inflammatory drugs (NSAIDs). It is the weakest of the NSAIDs but reversely has a prominent analgesic and antipyretic 
actions. Its mechanism of action concerns a non-selective inhibition of cyclooxygenase type 1 (COX-1) and cyclooxygen-
ase type 2 (COX-2). Its side effects are mainly due to the oral intake of this drug which produces an inhibitory action on 
cyclooxygenases, which are related with prostaglandins’ synthesis. Prostaglandins are associated with the production of 
pain, inflammation and fever. 
Extensive research has been put forward with the aim to improve the use of IBU in topical application to overcome its 
common side effects and low bioavailability (15, 16). Our group has described nanocrystal suspensions of IBU stabilized with 
a combination of surfactants and melt-emulsification processes (3, 4) using different types of surfactants. In this work, we 
highlight the combination of Tween® 80/Span® 80 to stabilize IBU nanocrystals in aqueous dispersion. Both surfactants 
are widely used in pharmaceutical formulation. These surfactants are generally recognized as safe (GRAS) as non-toxic, 
non-irritating and of low cost. The method production was based on homogenization because it is easily be performed 
on a small and large scale concerning industrial pharmaceutical.
The produced IBU-NCs were analyzed by particle size and PdI. The fresh sample showed a particle size and PdI of 159.4 
± 3.265 nm and 0.24 ± 0.007, respectively. The size of NCs formulation is dependent on the composition/concentration of 
formulation and method of production. Generally, the high homogenization produces small droplets due to high pressure 
and fast cooling. Particle size is important for skin permeation, and the ideal size for penetration of the skin is under 700 nm 
(17). Also, Lademann et al. (18), Adib et al. (19) suggested that a particle size between 300–600 nm promote drug penetration 
significantly more in-depth into the skin layer. The PdI is a parameter for defining the particle size distribution. Samples 
with a wide particle size distribution usually have a polydispersion index > 0.7 (20). PdI of 0.4 shows a heterogeneous particle 
size distribution, and the presence of agglomerates in the dispersion (21). In this study, the obtained PdI is attributed to the 
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rearrangements of polysorbate and sorbitan monooleate chains on the surface of nanocrystals. The obtained PdI value 
was considered low, and a homogeneous sample was produced.
The choice of cryoprotectant and its concentration is essential for obtaining a stable and reproducible product. The 
absence of cryoprotecting agents in the drying stage can occasionally produce NCs with sticky and thick components, 
and if reconstituted, there is the production of aggregates. Thus, the correct choice will allow easy redispersion of the 
freeze-dried formulation (22). As shown in Table I, the lyophilization slightly increased the mean particle size of IBU-NCs 
measured after their reconstitution with double distilled water, however remaining within the nanometer range. A low PdI 
could be seen in particular for the NCs:Glucose (3:1) combination. All IBU-NCs powders were of white, fine and uniform 
texture. The NCs:Trehalose (2:1), NCs:Glucose (3:1) and NCs:Sucrose (4:1) for further studies. 
In vitro release profile of ibuprofen from non-lyophilized nanocrystals has been compared with the profiles of the 
resuspended nanocrystals freeze-dried with different cryoprotectant, over a period of 24 hours (Figure 1). Selected cryo-
protectant was based on the lowest mean particle size and polydispersity index, namely NCs: Trehalose (2:1) of 170.6 ± 
3.880 nm (PI 0.417 ± 0.050), NCs:Glucose (3:1) of 275.3 ± 8.351 nm (PI 0.144 ± 0.021), and NCs:Sucrose (4:1) of 223.3 
± 10.35 nm (PI 0.402 ± 0.016), covered by a combination of Tween® 80 and Span® 80. 
As shown in Figure 1, the release profile allowed the identification of a burst release occurring within the first 10 min, 
during which approximately 50% of the drug was immediately released in all lyophilized samples. Within the first 6 h, 
NCs:Trehalose (2:1), NCs:Glucose (3:1) and NCs:Sucrose (4:1) released about 70%, 65% and 50% of the drug, respectively. 
The slower drug release observed among the samples can be attributed to the interaction between the surfactants, cryo-
protection and the drug. Within 24 h, all resuspended freeze-dried samples released almost 100% of the drug. A delayed 
release was observed for the non-lyophilized IBU nanocrystals; within the first 30 mins only 30% of the drug has been 
quantified in the receptor medium in contrast to ca. 55% of the lyophilized formulations. The higher hydration capacity of 
these latter justifies the higher cumulative IBU released over the course of the experiment.
According Patel et al., 2018 (23) the release profile observed in this study is typical of nanocrystal formulations. Nano-
crystal interact with skin overcoming the barrier and reaching cellular level and increase the saturation solubility and 
concentration gradient easing passive penetration through the skin. Also, this technology is widely used in cosmetics 
and ointments and emulsions to improve improve formulation stability, tolerance and obtain more product esthetically. 
Similar results were obtained by rutin (24), flavonoids (25) and quercetin (26).
Table I. Mean particle size (z-AVE) and polydispersity index (PdI) of ibuprofen nanocrystals before (non-lyophilized) 
and after lyophilization. Nanocrystals were re-suspended in ultra-purified water prior to measurements. 
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Figure 1. In vitro IBU release profiles of nanocrystals dispersions before freeze-drying (non-lyophilized) and after fre-
eze-drying with trehalose (2:1), Glucose (4:1) and Sucrose (3:1). Data were recorded at pre-defined time points for a 
period of 24 h.
Conclusions
The advantages of IBU nanocrystals as delivery system is attributed to the possibility to enhance the drug solubility and 
stability. Nanocrystals can be lyophilized to enhance their stability retaining their capacity to modify the release profile. 
The type and concentration of the cryoprotectant were found to influence the mean particle size, polydispersity index and 
release profile. 
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